Engineered Adenine Base Editors
Not specified
ResearchActive
Key Facts
About Metagenomi
Metagenomi is pioneering a new era of genetic medicine by harnessing the vast diversity of microbial life through metagenomics to discover and engineer next-generation genome editing tools. Founded by pioneers in the field, the company has built an industry-leading database, identified over 20,000 editing systems, and is advancing a pipeline of in vivo therapies for genetic diseases. With a strong leadership team, strategic partnerships, and a public listing, Metagenomi is positioned to expand its therapeutic reach and translate its novel platform into transformative patient cures.
View full company profileOther Not specified Drugs
| Drug | Company | Phase |
|---|---|---|
| Inflammation Programs | Arcus Biosciences | Not Specified |
| Bone Marrow Conditioning Program | Telix Pharmaceuticals | Pipeline |
| AGMB-447 | Agomab Therapeutics | Not Disclosed |
| AGMB-101 | Agomab Therapeutics | Not Disclosed |
| TRIFERTY-ATM® | Laboratorio Reig Jofre | Approved/Commercial |
| AGEN1571 (anti-ILT2) | Agenus | Not specified |
| AGEN1777 | Agenus | Not specified |
| AGEN1721 | Agenus | Not specified |
| INCAGN1876 (GITR Agonist) | Agenus | Not specified |
| INCAGN1949 (OX40 Agonist) | Agenus | Not specified |
| AGEN1327 (anti-TIGIT) | Agenus | Not specified |
| AGEN2373 (CD137 Agonist) | Agenus | Not specified |